Kennedy Capital Management LLC decreased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 30.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 269,652 shares of the biotechnology company's stock after selling 117,157 shares during the quarter. Kennedy Capital Management LLC owned 0.11% of ADMA Biologics worth $4,625,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its position in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares in the last quarter. National Bank of Canada FI acquired a new stake in ADMA Biologics during the third quarter valued at $35,000. Mark Sheptoff Financial Planning LLC purchased a new position in ADMA Biologics in the fourth quarter valued at $35,000. Vision Financial Markets LLC acquired a new position in shares of ADMA Biologics in the fourth quarter worth about $51,000. Finally, AlphaQuest LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter worth about $84,000. Hedge funds and other institutional investors own 75.68% of the company's stock.
ADMA Biologics Stock Performance
NASDAQ ADMA traded up $0.08 on Friday, reaching $21.31. The stock had a trading volume of 2,965,421 shares, compared to its average volume of 3,613,650. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a market cap of $5.04 billion, a P/E ratio of 76.11 and a beta of 0.53. The business's 50-day moving average price is $18.15 and its 200 day moving average price is $18.22. ADMA Biologics, Inc. has a 12-month low of $6.01 and a 12-month high of $23.64.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.
View Our Latest Report on ADMA Biologics
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Further Reading
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
